Healome Therapeutics, a spinout from the University of Birmingham, is seeking regulatory engagement with both the FDA and the MHRA.
3 reports, 1 independent
Updated Jul 7
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Healome Therapeutics, a spinout from the University of Birmingham, is seeking regulatory engagement with both the FDA and the MHRA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
University of Birmingham
university in Birmingham, England, United Kingdom
Nothing else this week.
Related events
- UK and US regulatory bodies are setting submission targets and offering R&D rebate programs to companies.
- Vera Therapeutics and the FDA agreed to shift the assessment of a clinical study.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.